MiCardia is a medtech company that reported a financing in a regulatory filing dated April 3, 2013. The company raised $3.7 million, as reported in an April 11, 2013 article. The financing instruments listed in the filing were debt and options/warrants. The filing showed participation from 17 investors. The report recorded $0 in sales commissions and $0 in finders’ fees. The article does not include operational metrics, product details, or stated future plans. MiCardia develops mitral valve repair devices and is marketing its enCorSQ Mitral Valve Repair System in the EU. The enCorSQ is an annuloplasty device that enables late, non‑surgical adjustment weeks to months after implantation to correct recurrent mitral regurgitation. The enCorSQ has been available for sale in the EU since January 2012. MiCardia completed an internal round of funding that will provide $4.4 million during 2012 and 2013 to expand commercialization of enCorSQ in Europe and select countries worldwide. The company holds 14 issued patents and multiple ongoing patent applications in mitral valve repair and has licensed its transcatheter mitral repair intellectual property to a newly formed spin‑out, ValCare. ValCare is developing a catheter‑delivered transcatheter mitral annuloplasty system and is backed by Accelmed Medical Partners LP, which committed $8.0 million to advance that technology and its IP.

Total raised

$8M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Apr 2013